NSE - Delayed Quote INR

SENORES PHARMACEUTICALS L (SENORES.NS)

Compare
502.85 -28.35 (-5.34%)
At close: 3:29:59 PM GMT+5:30
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
Total Revenue
2,107,870.00
2,107,870.00
353,260.00
140,680.00
Cost of Revenue
1,111,600.00
1,111,600.00
127,660.00
80,340.00
Gross Profit
996,270.00
996,270.00
225,600.00
60,340.00
Operating Expense
680,200.00
680,200.00
116,660.00
47,870.00
Operating Income
316,070.00
316,070.00
108,940.00
12,470.00
Net Non Operating Interest Income Expense
-89,870.00
-89,870.00
-20,990.00
-3,720.00
Pretax Income
249,440.00
249,440.00
124,370.00
11,430.00
Tax Provision
-77,640.00
-77,640.00
40,040.00
1,520.00
Net Income Common Stockholders
314,550.00
314,550.00
84,330.00
9,910.00
Diluted NI Available to Com Stockholders
314,550.00
314,550.00
84,330.00
9,910.00
Basic EPS
--
6.83
1.83
0.22
Diluted EPS
--
6.83
1.83
0.22
Basic Average Shares
--
46,053.59
46,053.59
46,053.59
Diluted Average Shares
--
46,053.59
46,053.59
46,053.59
Rent Expense Supplemental
8,970.00
8,970.00
1,400.00
140.00
Total Expenses
1,791,800.00
1,791,800.00
244,320.00
128,210.00
Net Income from Continuing & Discontinued Operation
314,550.00
314,550.00
84,330.00
9,910.00
Normalized Income
314,795.00
314,795.00
84,350.34
9,910.00
Interest Income
4,590.00
4,590.00
390.00
1,930.00
Interest Expense
85,000.00
85,000.00
18,370.00
5,100.00
Net Interest Income
-89,870.00
-89,870.00
-20,990.00
-3,720.00
EBIT
334,440.00
334,440.00
142,740.00
16,530.00
EBITDA
434,620.00
434,620.00
160,530.00
23,580.00
Reconciled Cost of Revenue
1,111,600.00
1,111,600.00
127,660.00
80,340.00
Reconciled Depreciation
100,180.00
100,180.00
17,790.00
7,050.00
Net Income from Continuing Operation Net Minority Interest
314,550.00
314,550.00
84,330.00
9,910.00
Total Unusual Items Excluding Goodwill
-350.00
-350.00
-30.00
--
Total Unusual Items
-350.00
-350.00
-30.00
--
Normalized EBITDA
434,970.00
434,970.00
160,560.00
23,580.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-105.00
-105.00
-9.66
--
3/31/2022 - 12/30/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers